“A massive detox plan” cured women’s cancer, she says
Liana Werner-Gray believes she would not have beaten cancer if she hadn’t made any major changes to her diet and lifestyle. Fox News Digital spoke to the author and Wellness Advocate about her health journey.
There may be new hope on the horizon Kidney cancer Patients in the form of experimental vaccines.
Researchers from the Dana-Farber Cancer Institute, Harvard Medical School, Yale Cancer Center, and other universities have published early detections from the study. Antitumor vaccine For patients with advanced kidney cancer.
“Participants with stage 3 or 4 kidney cancer are at a higher risk of recurrence,” said Toni Choueli, MD, director of Dana Farmer’s Rank Genuro Cancer Center, co-author and co-investigation in a press release. Officer Toni Choueli, MD, said.
Cardiologists say the illness starts from your dish – here’s what should change
“The tools that need to reduce that risk aren’t perfect, they’re mercilessly looking for more.”
There may be new hope on the horizon for kidney cancer patients in the form of experimental vaccines. (istock)
After undergoing surgery to remove a malignant tumor, nine participants received a cancer vaccine aimed at “training” their immune systems to identify and attack residual cancer cells, according to a press release. I did.
Each vaccine was personalized to match the tumor type of individual patients based on cancer cells removed during the surgery. These cells contain “neoantigen,” a “small fragment of a mutein,” the release states. Researchers use “prediction algorithms” to determine which neoantigens should be included in the vaccine. The highest level of immunity.
This US prostate cancer case is skyrocketing as doctors probably share the reason
Five patients were also given ipilimumab, a type of immunotherapeutic drug.
All nine patients showed “successful anti-cancer immune responses” after receiving the vaccine. After an average of 34.7 months, they all remained cancerous.
Within three weeks of receiving the vaccine, patients have shown a “immune response” and T cells have skyrocketed over 166 times, the release said. (T cells, also known as T lymphocytes, are immune cells that help fight cancer and prevent infection.)
“The tools that need to reduce that risk aren’t perfect, and we’re mercilessly looking for more.”
This study found that T cells remained in the patient’s body for up to three years, attacking existing tumor cells.
“We observed a rapid, substantially durable and durable expansion of new vaccine-related T-cell clones,” said Patrick Ott, MD, director of the Cancer Vaccine Center at Dana-Farber. It’s there.
“These results require extensive research to fully understand the clinical efficacy of this approach, but create highly immunogenic, personalized, new antigenic vaccines for lower mutation-loaded tumors. It supports the possibility of doing so.”
For most stage 3 or 4 renal cancer patients, the standard treatment is surgical removal of the tumor, often followed by immunotherapeutic agents. (istock)
The results of the clinical trial were reported in Nature on February 5th.
“We are very excited by these results that show such positive responses in all nine patients with kidney cancer,” Choueiri pointed out.
For most stage 3 or 4 renal cancer patients, standard care is surgical removal of the tumor. Immunotherapy drugs It is called pembrolizumab (keytruda).
Common cancer types can be detected with new blood tests
“Pembrolizumab induces an immune response that reduces the risk of cancer returning,” says Dana Farmer. “However, about two-thirds of patients may have recurring and treatment options may be limited.”
First author David A. Brown, MD, PhD, a Medical Oncologist Physician scientists at Yale Cancer Center and Yale School of Medicine said the approach used in the study was “a completely different from attempts to vaccines for kidney cancer.”
“We select cancer-specific targets and are different from normal parts of the body, so our immune system can effectively “steer” cancer in a very specific way,” the study said. The person said in the release. (istock)
“We choose cancer-specific targets and are different from normal parts of the body, so our immune system can effectively “steer” cancer in a very specific way,” Brown releases. I mentioned it in.
“We have learned whether certain targets of cancer are most susceptible to immune attacks, demonstrating that this approach can generate long-term immune responses and direct the immune system to recognize cancer. Newborn vaccine Kidney cancer. ”
“Exciting and promising”
Charles Nuguen, MD, a medical oncologist specializing in kidney cancer in Hope City, Orange County, California, says that kidney cancer is one of the 10 most common cancers among men and women in the US. I pointed out.
“This is a very exciting and promising tool for many patients with kidney cancer, and one day we can enable treatment for everyone.”
“People with early stage (localized) kidney cancer are often the first It will be treated with surgery To remove tumors – but many patients are at risk of cancer returning several years after surgery, and there is a great interest in finding ways to reduce the risk of cancer recurrence,” the study said. Nguyen, who was not involved, said. Fox News Digital.
“This exciting clinical trial used each patient’s cancer genetic information to train and strengthen the patient’s immune system, to recognize cancer and to evaluate individual cancer vaccines to prevent recurrence. ”
Click here to get the Fox News app
Nguyen admitted that this was a small study, but all nine patients who received the vaccine were cancer-free even three years later.
“This is a very exciting and promising tool for many patients with kidney cancer, and one day we can enable treatment for everyone.”
Side effects and limitations
Some patients have experienced side effects from the vaccine, including local reactions at the site of the vaccine and flu-like symptoms, but “no high-quality side effects have been reported.”
Click here to sign up for our health newsletter
The researchers also acknowledged that there are several limitations related to the study.
“The antigen prediction tools available at the time and the ability to target only a single antigen were limited,” they wrote.
Some patients experienced side effects from the vaccine, including local reactions at the site of the vaccine and flu-like symptoms. (istock)
“In addition, it was carried out in an active metastatic disease setting with many study participants.”
Future research Larger clinical trials are being planned to confirm the effectiveness and full potential of the vaccine, the release states.
Visit us for more health articles www.foxnews.com/health
The research was funded by the Gateway for Cancer Research, US Department of Defense, Yale Cancer Center, Dana Farmer/Harvard Cancer Center, Harvard Medical School, Trust Family Foundation, Michael Brigham, Pan Mass. Challenge, provided by Hinda L. The Arthur Marcus Foundation, the Loker Pinerard Fund for Kidney Cancer Research at the Dana Farber Cancer Institute, the National Institutes of Health and the Conquest Cancer Foundation/Sontag Foundation’s Conquest Foundation.
